GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (NAS:CMRX) » Definitions » Shiller PE Ratio

Chimerix (Chimerix) Shiller PE Ratio : (As of Apr. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chimerix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Chimerix Shiller PE Ratio Historical Data

The historical data trend for Chimerix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix Shiller PE Ratio Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Chimerix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Chimerix's Shiller PE Ratio

For the Biotechnology subindustry, Chimerix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chimerix's Shiller PE Ratio falls into.



Chimerix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chimerix's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Chimerix's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.21/129.4194*129.4194
=-0.210

Current CPI (Dec. 2023) = 129.4194.

Chimerix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.390 99.695 -0.506
201406 -0.390 100.560 -0.502
201409 -0.470 100.428 -0.606
201412 -0.520 99.070 -0.679
201503 -0.540 99.621 -0.702
201506 -0.590 100.684 -0.758
201509 -0.700 100.392 -0.902
201512 -0.820 99.792 -1.063
201603 -0.570 100.470 -0.734
201606 -0.390 101.688 -0.496
201609 -0.370 101.861 -0.470
201612 -0.320 101.863 -0.407
201703 -0.380 102.862 -0.478
201706 -0.360 103.349 -0.451
201709 -0.370 104.136 -0.460
201712 -0.410 104.011 -0.510
201803 -0.420 105.290 -0.516
201806 -0.390 106.317 -0.475
201809 -0.330 106.507 -0.401
201812 -0.290 105.998 -0.354
201903 -0.350 107.251 -0.422
201906 -0.350 108.070 -0.419
201909 -1.260 108.329 -1.505
201912 -0.060 108.420 -0.072
202003 -0.170 108.902 -0.202
202006 -0.160 108.767 -0.190
202009 -0.180 109.815 -0.212
202012 -0.190 109.897 -0.224
202103 -1.210 111.754 -1.401
202106 -0.210 114.631 -0.237
202109 -0.210 115.734 -0.235
202112 -0.450 117.630 -0.495
202203 -0.280 121.301 -0.299
202206 -0.270 125.017 -0.280
202209 2.750 125.227 2.842
202212 -0.240 125.222 -0.248
202303 -0.240 127.348 -0.244
202306 -0.210 128.729 -0.211
202309 -0.270 129.860 -0.269
202312 -0.210 129.419 -0.210

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chimerix  (NAS:CMRX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Chimerix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Chimerix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (Chimerix) Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.
Executives
Fred A Middleton director 400 SOUTH EL CAMINO REAL STE 1200, SAN MATEO CA 94402-1708
David Jakeman officer: Principal Accounting Officer C/O CHIMERIX, INC.,, 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Michael A. Sherman director, officer: Chief Executive Officer 3000 KENT AVE STE A1-100, WEST LAFAYETTE IN 47906
Martha J Demski director 7770 REGENTS ROAD SUITE 113-505, SAN DIEGO CA 92122
Robert J. Meyer director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Michael T. Andriole officer: Chief Business Officer C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Cantex Pharmaceuticals, Inc. 10 percent owner 1792 BELL TOWER LANE, SUITE 222, WESTON FL 33326
Victoria Vakiener director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Allen S. Melemed officer: Chief Medical Officer C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM NC 27713
Pratik S Multani director C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Michael Albert Alrutz officer: Principal Executive Officer 2530 MERIDIAN PARKWAY, 2ND FLOOR, DURHAM NC 27713
M Michelle Berrey officer: Chief Medical Officer 303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Ernest Mario director 20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Ed Greissing director 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713